4 months ago
ADVM
AnalystsDaniil GataulinDaniil Gataulin's Stock Forecasts
AnalystsDaniil Gataulin
Sectors:
Industries:
Analyst Ranking
Bottom 3%
#4312 out of 4414 analysts
Average Return
-26.18%
Win Rate
29%6 out of 21
Risk vs Reward
Poor
Good
Daniil Gataulin's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eyepoint Pharmaceuticals IncEYPT | +86.81% | $3.26 | $6.09 | 2023-03-03 - 2023-11-28 | Strong Buy |
Oyster Point Pharma IncOYST | +45.60% | $7.96 | $11.59 | 2022-08-11 - 2022-11-08 | Strong Buy |
Applied Genetic Technologies CorpAGTC | +35.86% | $0.29 | $0.39 | 2022-09-28 - 2022-11-30 | Strong Buy |
Regenxbio IncRGNX | +9.95% | $17.48 | $19.22 | 2023-08-03 - 2023-11-28 | Strong Buy |
Eyepoint Pharmaceuticals IncEYPT | +7.76% | $7.99 | $8.61 | 2022-07-07 - 2023-07-06 | Strong Buy |
Daniil Gataulin Analyst Color
Get additional color on Daniil Gataulin's coverage of popular stocks
Daniil Gataulin's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Outlook Therapeutics IncOTLK | 3 | Strong Buy | $10.00 | +1,966.12% | Reiterates | 3 months ago |
Adverum Biotechnologies IncADVM | 3 | Strong Buy | $4.00 | +388.40% | Upgrades | 4 months ago |
Regenxbio IncRGNX | 5 | Strong Buy | $55.00 | +186.16% | Reiterates | 4 months ago |
Eyepoint Pharmaceuticals IncEYPT | 4 | Strong Buy | $22.00 | +261.25% | Reiterates | 4 months ago |
Ocugen IncOCGN | 3 | Strong Buy | $4.00 | +958.20% | Maintains | 7 months ago |
Korro Bio IncKRRO | 1 | Strong Buy | $7.00 | -82.46% | Initiates Coverage On | a year ago |
Oyster Point Pharma IncOYST | 2 | Hold | $13.00 | N/A | Downgrades | a year ago |
Applied Genetic Technologies CorpAGTC | 2 | Strong Buy | $3.00 | N/A | Maintains | a year ago |
Kodiak Sciences IncKOD | 1 | Strong Buy | $18.00 | N/A | Maintains | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.